Osteologix and Servier enter ex-US osteo drug licensing deal worth a potential 42 million euros

USA-based Osteologix, through its wholly owned Irish subsidiary Osteologix, has granted Servier Research Group, the leading French independent pharmaceutical company, an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) to treat post-menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the USA. NB S101 is an innovative molecule acting on both bone formation and bone resorption.

Under the terms of the agreement, Osteologix will receive up to 12 million euros ($15.6 million) in upfront and milestone payments. Additionally, Osteologix is eligible to receive up to 30 million euros in minimum royalty payments creditable against mid to low single digit royalties on sales. Osteologix will also be eligible for milestone payments and royalties on product development and sales in Japan. The accord is subject to customary termination provisions.

Servier will be responsible for all costs outside of the USA associated with development, regulatory approval and commercialization of NB S101. Osteologix will continue to own intellectual property rights for development in the USA.